2. Signaling Pathways
  3. GPCR/G Protein
    Neuronal Signaling
  4. Neuropeptide Y Receptor
  5. Neuropeptide Y Receptor Isoform

Neuropeptide Y Receptor

 

Neuropeptide Y Receptor Related Products (119):

Cat. No. Product Name Effect Purity
  • HY-P3212
    Allo-aca
    		Antagonist 99.82%
    Allo-aca, a leptin peptidomimetic, is a potent, specific leptin receptor antagonist peptide. Allo-aca blocks leptin signaling and action in numerous in vitro and in vivo models.
  • HY-P0198
    Neuropeptide Y (human,rat,mouse)
    		99.94%
    Neuropeptide Y (human,rat,mouse) is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.
  • HY-P1514
    Peptide YY (PYY), human
    		99.17%
    Peptide YY (PYY) is a gut hormone that regulates appetite and inhibits pancreatic secretion. Peptide YY (PYY) can mediate its effects through the Neuropeptide Y receptors.
  • HY-100717
    HT-2157
    		Antagonist 98.0%
    HT-2157 (SNAP 37889) is a selective, high-affinity, competitive antagonists of galanin-3 receptor (Gal3).
  • HY-P1601
    Neuropeptide Y(29-64)
    		99.85%
    Neuropeptide Y(29-64) is a 36 amino acid peptide, a fragment of Neuropeptide Y.
  • HY-P11291A
    NNC0165-1273 TFA
    NNC0165-1273 (TFA) is the trifluoroacetic acid of NNC0165-1273 (HY-P11291). NNC0165-1273 is an analog of gut hormone peptide YY (PYY3-36). NNC0165-1273 has a superior affinity for Y2 receptor over Y1, Y4, and Y5 receptor. NNC0165-1273 has a potent anorectic effect and significantly reduces nighttime and ghrelin-induced food intake by producing early satiety. NNC0165-1273 inhibits ghrelin-induced cFos expression in NPY/AgRP neurons. NNC0165-1273 can be used for antiobesity therapies research.
  • HY-P11044
    GEP12
    		Agonist
    GEP12 is a GLP-1R/Y1-R/Y2-R tri-receptor agonist peptide with an EC50 of 17.3 nM and an IC50 of 19.2 nM for receptor binding. GEP12 may promote glycemic control and weight loss.
  • HY-P1327
    BVD 10
    		Antagonist
    BVD 10, a neuropeptide Y (NPY) analogue peptide, is a highly selective NPY Y1 receptor antagonist. BVD10 significantly prevents NPY-induced glutamate increase. BVD 10 can be used for seizure research.
  • HY-P0198A
    Neuropeptide Y (human,rat,mouse) TFA
    		99.57%
    Neuropeptide Y (human) TFA is involved in Alzheimer's disease (AD) and protects rat cortical neurons against β-Amyloid toxicity.
  • HY-P1127
    Galanin (1-30), human
    		Agonist 99.91%
    Galanin (1-30), human is a 30-amino acid neuropeptide, and acts as an agonist of GalR1 and GalR2 receptors, with Kis of both 1 nM.
  • HY-P1130
    M871
    		Antagonist 99.98%
    M871 (Galanin-(2-13)-Glu-His-(Pro)3-(Ala-Leu)2-Ala-amide) is an orally active and selective galanin receptor type 2 (GalR2) antagonist. M871 exhibits Ki values of 13.1 nM, 420 nM and >10 μM for GalR2, GalR1 and GalR3 respectively. M871 relieves the mice allergic rhinitis by reducing IgE production, as well as the number of B cells in tissues. M871 can inhibit the nerve invasion of salivary adenoid cystic carcinoma (SACC) and alleviate myocardial ischemia-reperfusion injury. M871 can be used for research on GalR2-related diseases (such as epilepsy, pain).
  • HY-14450
    JNJ-31020028
    		Antagonist 98.02%
    JNJ-31020028 is a selective and brain penetrant antagonist of neuropeptide Y Y2 receptor with pIC50 values of 8.07 and 8.22 for human and rat Y2 receptor, respectively. JNJ-31020028 can be used for the research of nervous disease.
  • HY-P1723
    Spexin
    		Agonist 99.94%
    Spexin (Neuropeptide Q) is a selective agonist of galanin receptors GAL2 and GAL3, and is a conserved peptide that functions as a neurotransmitter/neuromodulator and endocrine factor. Spexin can function through both central and peripheral actions. Spexin upregulates Beclin 1 to inhibit ferroptosis induced by excessive autophagy, reduces the uptake of long-chain fatty acids by adipocytes, and regulates energy metabolism by increasing lipid oxidation (e.g., reducing the respiratory exchange ratio in rodents). Spexin improves cardiac function in the Doxorubicin hydrochloride (HY-15142)-induced cardiotoxicity model, protects mitochondrial membrane potential, and reduces iron accumulation and lipid peroxidation. Spexin can be used to study obesity and its related metabolic disorders, cardiovascular diseases (e.g., cardioprotection), and side effects of tumor chemotherapy.
  • HY-P0199
    Pancreatic Polypeptide, human
    		Agonist 99.82%
    Pancreatic Polypeptide, human is a C-terminally amidated 36 amino acid peptide, which acts as a neuropeptide Y (NPY) Y4/Y5 receptor agonist.
  • HY-P1131
    M617
    		Agonist 99.54%
    M617 is a selective galanin receptor 1 (GAL1) agonist, with Kis of 0.23 and 5.71 nM for GAL1 and GAL2, respectively. M617, acting through its central GAL1, can promote GLUT4 expression and enhance GLUT4 content in the cardiac muscle of type 2 diabetic rats.
  • HY-W012999
    Tiglic acid
    		99.97%
    Tiglic acid is a monocarboxylic unsaturated organic acid. Tiglic acid can be isolated from croton oil. Tiglic acid agonizes FFA2 and upregulates PYY expression. Tiglic acid derivatives have anti-inflammatory activity. Tiglic acid can be used in the research of obesity, diabetes, and inflammatory diseases.
  • HY-P1840
    Galanin Receptor Ligand M35
    		Antagonist 99.59%
    Galanin Receptor Ligand M35 is a high-affinity ligand and antagonist of galanin receptor (Kd=0.1 nM). Galanin Receptor Ligand M35 exerts a Ki values of 0.11 and 2.0 nM for human galanin receptor type 1 and 2, respectively.
  • HY-P1135
    M1145
    		Agonist 99.60%
    M1145, a chimeric peptide, is a selective galanin receptor type 2 (GAL2) agonist, with a Ki of 6.55 nM. M1145 shows more than 90-fold higher affinity for GAL2 over GAL1 (Ki=587 nM) and a 76-fold higher affinity over GalR3 (Ki=497 nM). M1145 has an additive effect on the signal transduction of galanin.
  • HY-P990631
    Mibavademab
    		Inhibitor ≥99.0%
    Mibavademab is a CHO-expressed humanized antibody that targets LEPR/CD295. Mibavademab is equipped with a huIgG4SP heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.58 kDa. The isotype control for Mibavademab can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
  • HY-124767
    SR 142948A
    		Antagonist 99.0%
    SR 142948A is a non-peptide neuropeptide neuropeptin (NT) receptor antagonist. SR 142948A is able to bind to neuropeptin receptors, especially with high affinity for NT1 and NT2 receptors. SR 142948A is mainly used to study the role of neuropeptide in the neurotransmitter system, especially the dopamine system.